Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

Ophthalmic Pharmaceuticals, Market Analysis, Forecasts and Dynamics - 2009-2023

BioNewsCast Press Release Distribution Service

Statins: The World Market, 2009-2024

Liver Cancer Drug Pipeline Update 2008

Bioinformatics Markets

New Products

Live Cell & Kinetic HCS Imaging Trends 2008

2008 Trends to Watch: Healthcare Technology

2009 Trends to Watch: Healthcare Technology

Biosimilars Series: Stakeholder Analysis

Biotech M&A Strategies: Deal assessments, trends and future prospects

Building a Network of Networks to Achieve Interoperability in Healthcare (Strategic Focus)

Business Trends - Healthcare Technology (Customer Focus)

Claims Processing for Healthcare Payers (Market Model)

Clinical Decision Support in Healthcare - One step closer to the Omniscient Clinician (Strategic Focus)

Commercial and Pipeline Insight: ADHD - Immature adult market continues to offer greatest commercial potential

BioPortfolio | Medtech Ventures

Endovascular Aneurysm Repair Device Market Paradigm Shift & Strategic Opportunities
The global market for endovascular aneurysm repair devices was estimated at $1,750 million in 2008, a growth rate of 17% over its 2007 level of $1,500 million. Over the past five years the market has been growing at a compound average annual growth rate (CAAGR) of 18%.

Aortic EndoGraft Market Current Situation and Future Outlook
In September 1990 Juan Parodi performed the first endovascular aortic aneurysm repair in Buenos Aires. Eighteen years later the Market for Endovascular Aortic Stent Grafts (EndoGrafts) touched the one billion dollar mark globally and is still going strong growing at double digit rates.

Endovascular Cerebral Aneurysm Repair Market Current Situation & Future Outlook
The market for Endovascular Cerebral Aneurysm Repair (ECAR) has grown significantly since its inception in the mid-90s and the devices available for use in such procedures have evolved rapidly since the introduction of Guglielmi Detachable Coils (GDC) over a decade ago.

Abdominal Aortic Aneurysm Endovascular Technology and Market Forecasts
It is estimated that approximately 4.5 million people in the developed word are living with an abdominal aortic aneurysm and each year 600,000 new cases are diagnosed.

Patients typically have no symptoms and, when they are diagnosed, they often undergo complex open surgical repair. Stent-graft therapy provides a minimally-invasive alternative, with reduced recovery times and potentially improved survival rates.

Thorcic Aortic Aneurysm and Dissection Endovascular Technology and Market Forecast
An estimated 35,000 thoracic aortic surgical and endovascular interventions are performed every year in the developed world (10,000 in the US alone) at a combined cost to individuals, insurance companies and tax payers of $3.5 billion a year.

Femoro-Popliteal Angioplasty and Stenting
The market for Fem-Pop Angioplasty & Stenting has experienced explosive growth recently mainly due to the launch and acceptance of novel atherectomy devices like the SilverHawk, and the regulatory approval of dedicated Stents.

At the end of 2005 the market was estimated at $470 million, growing by 30% over the previous year.

Neuro Stents & Coils Technology Market Forecast
The market for Neuro-Endovascular Devices which currently stands at $590 million is expected to reach $1.1 billion by 2012.

The increase in use of non-invasive neuro-imaging modalities in the outpatient setting has led to a sharp increase in the number of truly asymptomatic, intracranial aneurysms being diagnosed.

Continuous improvement in coil design and composition, the introduction of stents for the management of wide-necked cerebral aneurysms and the advancement in guiding catheters and wire designs are improving the utility of coils in intracranial aneurysm repair.

Drug Eluting Coronary Stents Market - Current Situation & Future Outlook
The Market for Drug Eluting Coronary Stents grew by 3% in 2008 reaching $4.2 Billion globally. Decline in average selling price was offset by growth in procedure volume and improved penetration levels.

The US market remained stable at $1.8 billion accounting for 43% of the world market. The launch of Medtronic's Endeavor zotarolimus-eluting stent and Abbott's & Boston Scientific's Xience and Promus everolimus-eluting stents during the year, redistributed market shares with JnJ's Cypher losing the most.

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions